Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

about

Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

P2860

Q47661007-1C3A99DA-B163-4E6D-968E-38FD47F8B9DB

P2860

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

Item

http://www.wikidata.org/entity/Q53463994

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Population PBPK modelling of t ...... inter-individual variability.

@en

Population PBPK modelling of t ...... inter-individual variability.

@nl

type

Item

label

Population PBPK modelling of t ...... inter-individual variability.

@en

Population PBPK modelling of t ...... inter-individual variability.

@nl

prefLabel

Population PBPK modelling of t ...... inter-individual variability.

@en

Population PBPK modelling of t ...... inter-individual variability.

@nl

P1476

Population PBPK modelling of t ...... inter-individual variability.

@en

P2093

Abdullah Hamadeh

http://www.w3.org/2001/XMLSchema#string

Andrea N Edginton

http://www.w3.org/2001/XMLSchema#string

Colin Phipps

http://www.w3.org/2001/XMLSchema#string

Paul R V Malik

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2.

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.

An estimation of the number of cells in the human body.

Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.

An integrated model of epidermal growth factor receptor trafficking and signal transduction.

Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies.

P2888

s10928-017-9515-3

P304

277-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10928-017-9515-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28260166

http://www.w3.org/2001/XMLSchema#string

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

about

P2860

P2860

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698